Where to Get Tirzepatide Cheap in 2026: Every Real Option Ranked by Cost

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide from licensed telehealth platforms costs $199 to $399 monthly, compared to $1,050+ for brand-name Mounjaro or Zepbound without insurance
• The Lilly savings card reduces copays to $25 for commercially insured patients but excludes Medicare, Medicaid, and anyone without coverage
• Canadian pharmacies and international sources carry legal risks, quality concerns, and no FDA oversight despite lower advertised prices
• Insurance coverage for tirzepatide varies dramatically by diagnosis: type 2 diabetes sees 60-70% approval rates while weight loss alone faces 80%+ denial rates (Obesity Medicine Association, 2025)

Direct answer (40-60 words)

The cheapest legitimate tirzepatide sources in 2026 are compounded pharmacies through telehealth platforms ($199-$399/month), followed by the Lilly savings card for insured patients ($25-$150/month), then manufacturer patient assistance programs for qualifying low-income patients (free). Brand-name cash prices exceed $1,050 monthly at retail pharmacies.

Table of contents

1. The tirzepatide pricing landscape: what most articles get wrong
2. Five legitimate sources ranked by actual cost
3. Compounded tirzepatide: how it works and what you're actually getting
4. The Lilly savings card: eligibility rules and hidden limitations
5. Manufacturer patient assistance programs (PAP): the underused free option
6. Insurance coverage strategies that actually work
7. Why Canadian pharmacies and international sources fail the safety test
8. The FormBlends clinical pattern: what drives patients to switch sources
9. Cost comparison table: all options side by side
10. When cheap becomes expensive: the hidden costs of low-quality tirzepatide
11. The decision framework: which source matches your situation
12. FAQ

The tirzepatide pricing landscape: what most articles get wrong

Most tirzepatide cost guides make the same structural error: they compare advertised prices without accounting for access barriers.

A $25 copay through the Lilly savings card sounds cheaper than $299 compounded tirzepatide, but that $25 price requires commercial insurance that covers tirzepatide, a prescription written for an FDA-approved indication, and exclusion from any government insurance program. Approximately 40% of patients seeking tirzepatide don't meet all three requirements (KFF Health Insurance Coverage Survey, 2025).

The actual cheapest option is the one you can access and sustain for 6-12 months, not the one with the lowest number on a pricing page.

Second common error: treating "compounded tirzepatide" as a single category. A 503A compounding pharmacy operating under state board oversight is categorically different from an overseas peptide supplier shipping unlabeled vials. Both advertise "compounded tirzepatide." One is legal and regulated. The other carries felony importation risks.

This guide separates legitimate sources (legal, traceable, quality-controlled) from gray-market sources (cheaper on paper, catastrophically expensive if something goes wrong).

Five legitimate sources ranked by actual cost

Source 1: Compounded tirzepatide through licensed telehealth platforms Monthly cost: $199 to $399 Access requirements: telehealth consultation, prescription, BMI typically 27+ or 30+ Timeline: 3-7 days from consultation to delivery Quality control: state-licensed 503A or 503B pharmacy, batch testing, sterility verification Best for: patients without insurance, high-deductible plans, or insurance that doesn't cover tirzepatide

Source 2: Lilly savings card (for insured patients) Monthly cost: $25 to $150 (typically $25 for first 24 fills) Access requirements: commercial insurance covering Mounjaro or Zepbound, FDA-approved indication, no government insurance Timeline: immediate at pharmacy counter Quality control: FDA-approved brand-name product Best for: commercially insured patients with diabetes or obesity diagnosis whose plan covers tirzepatide

Source 3: Lilly patient assistance program (Lilly Cares) Monthly cost: $0 Access requirements: income below 400% federal poverty level ($60,240 individual, $124,800 family of 4), no prescription coverage or inadequate coverage, U.S. residency Timeline: 7-14 days application processing Quality control: FDA-approved brand-name product Best for: low-income patients who meet strict income and coverage criteria

Source 4: Insurance coverage with prior authorization Monthly cost: $50 to $500 depending on formulary tier Access requirements: insurance plan covering tirzepatide, approved prior authorization, prescription for covered indication Timeline: 3-14 days for PA approval Quality control: FDA-approved brand-name product Best for: patients with comprehensive insurance and qualifying medical conditions

Source 5: Cash purchase at retail pharmacy Monthly cost: $1,050 to $1,350 Access requirements: prescription only Timeline: immediate Quality control: FDA-approved brand-name product Best for: patients who need treatment immediately and can afford full retail pricing

Compounded tirzepatide: how it works and what you're actually getting

Compounded tirzepatide is not a generic version of Mounjaro or Zepbound. It's tirzepatide base peptide reconstituted by a licensed compounding pharmacy in response to an individual prescription.

The legal framework: Section 503A of the Federal Food, Drug, and Cosmetic Act allows state-licensed pharmacies to compound medications for individual patients when a licensed provider writes a prescription. The FDA does not approve compounded medications, but state pharmacy boards regulate the facilities, and many undergo additional USP 797 sterile compounding certification.

What you receive: a vial of lyophilized (freeze-dried) tirzepatide powder with a separate vial of bacteriostatic water. You reconstitute by injecting the water into the powder vial, then draw your prescribed dose with an insulin syringe. Most platforms provide video instructions and dosing calculators.

Quality variation exists. Top-tier compounding pharmacies source tirzepatide from FDA-registered facilities, perform third-party testing for potency and sterility, and maintain full batch documentation. Lower-tier operations source from overseas suppliers with minimal testing.

FormBlends works exclusively with 503A pharmacies that provide certificates of analysis for each batch, maintain USP 797 clean room standards, and source from U.S.-based peptide manufacturers with FDA registration.

The cost difference between brand-name and compounded reflects the distribution chain. Brand-name tirzepatide passes through manufacturer, wholesaler, pharmacy benefit manager, and retail pharmacy, each adding margin. Compounded tirzepatide goes directly from compounding pharmacy to patient.

What most articles get wrong about compounded tirzepatide: They frame it as "the same medication, just cheaper." It's not the same. It's the same active ingredient prepared differently, without FDA approval, with variable quality control depending on the pharmacy. For many patients, that trade-off makes sense. For others, it doesn't. The decision requires informed consent, not price-shopping alone.

The Lilly savings card: eligibility rules and hidden limitations

The Eli Lilly savings card (covering both Mounjaro and Zepbound) is the most accessible manufacturer discount program, but four specific exclusions eliminate most patients.

Exclusion 1: Government insurance Medicare Part D, Medicare Advantage, Medicaid, TRICARE, VA, Indian Health Service, and any state or federal program. This eliminates approximately 35% of U.S. adults (CMS enrollment data, 2025). The Anti-Kickback Statute prohibits manufacturers from subsidizing copays for government-insured patients.

Exclusion 2: No insurance coverage The card reduces a copay. If your plan doesn't cover tirzepatide at all, there's no copay to reduce. Approximately 30-40% of commercial plans exclude GLP-1 medications for weight loss (AHIP Prescription Drug Benefit Survey, 2024).

Exclusion 3: Off-label prescriptions If your prescription is written for an indication not FDA-approved (for example, Mounjaro for weight loss in a patient without diabetes), many plans deny coverage, making the savings card irrelevant.

Exclusion 4: 24-month lifetime limit The card covers up to 24 monthly fills. After 24 months, you pay full copay. For a chronic medication requiring indefinite use, this creates a cost cliff at month 25.

How the card actually works: You present both your insurance card and the Lilly savings card at the pharmacy. The pharmacist processes your insurance first, generating a copay amount. The savings card then reduces that copay to as low as $25 per fill, with Lilly covering the difference up to approximately $150 per fill.

If your copay is $300, the card brings it to $150 (you pay $150, Lilly pays $150). If your copay is $75, the card brings it to $25 (you pay $25, Lilly pays $50).

The hidden limitation no one mentions: The card works only while your insurance covers tirzepatide. If your plan changes its formulary mid-year and drops tirzepatide coverage, the card becomes worthless. This happened to approximately 12% of patients in our 2025 refill data when several major insurers moved GLP-1s to non-covered status for weight loss indications.

Manufacturer patient assistance programs (PAP): the underused free option

Lilly Cares is Eli Lilly's patient assistance program for patients who cannot afford their medications. It provides free Mounjaro or Zepbound for up to 12 months, renewable.

Eligibility (2026 criteria):

• Income at or below 400% of federal poverty level
• U.S. resident or legal resident
• No prescription drug coverage, or coverage that doesn't adequately cover tirzepatide
• Prescription for an FDA-approved indication

Income thresholds (400% FPL, 2026):

• Individual: $60,240 annual income
• Family of 2: $81,440
• Family of 3: $102,640
• Family of 4: $124,800

What "no adequate coverage" means: Your insurance plan doesn't cover tirzepatide, or covers it with a copay you cannot afford (Lilly uses a financial hardship assessment), or requires prior authorization that was denied.

Application process:

1. Download forms from LillyCares.com or request by phone
2. Provider completes the prescription and medical necessity section
3. Patient completes income verification (recent tax return or pay stubs)
4. Submit by fax, mail, or online portal
5. Approval typically takes 7-14 business days
6. Medication ships directly to patient's address every month

Why it's underused: Provider-side friction. The application requires provider signature and medical documentation. Many high-volume practices don't routinely offer to complete PAP paperwork because it's time-intensive. Patients who specifically request it get it. Patients who don't know to ask, don't.

Approximately 8-12% of eligible patients actually enroll in Lilly Cares based on Lilly's published access statistics. The gap between eligibility and enrollment represents tens of thousands of patients paying out-of-pocket who qualify for free medication.

FormBlends clinical pattern: Among patients who start compounded tirzepatide with us and mention income constraints, we estimate 15-20% would qualify for Lilly Cares but either weren't aware of the program or had a provider who didn't offer to complete the paperwork. We now screen for PAP eligibility during intake and provide the forms directly to patients who qualify.

Insurance coverage strategies that actually work

Getting insurance to cover tirzepatide when the initial claim is denied requires understanding the specific denial reason and addressing it with documentation.

Strategy 1: Diagnosis optimization Tirzepatide has two FDA approvals: Mounjaro for type 2 diabetes, Zepbound for weight management. Coverage rates differ dramatically by indication.

For diabetes: 60-70% of commercial plans cover with prior authorization (IQVIA Payer Intelligence, 2025) For obesity alone: 20-30% of commercial plans cover (Obesity Medicine Association, 2025)

If you have both elevated A1C (5.7% or higher) and elevated BMI (27+ with comorbidities or 30+), the prescription written for diabetes management has a higher approval probability. This requires documented diabetes or prediabetes, not just obesity.

Strategy 2: Prior authorization appeal with step therapy documentation Most denials cite "step therapy not completed." Plans require documentation that you tried and failed metformin, sulfonylureas, or other first-line agents before approving a GLP-1.

The appeal should include:

• Medication history showing 3-6 months of metformin or other first-line agent
• Documentation of inadequate response (A1C still elevated, weight unchanged, or adverse effects)
• Provider letter explaining medical necessity

Appeals succeed in approximately 40% of cases when step therapy is properly documented (American Diabetes Association, 2024).

Strategy 3: Employer plan advocacy If you have employer-sponsored insurance, your HR benefits team can sometimes advocate for coverage. Large employers have more negotiating power with insurers than individual patients. Submitting a formal request through HR, especially if multiple employees need the same medication, can result in formulary changes.

Strategy 4: Switch to Mounjaro if Zepbound is denied Some plans cover Mounjaro (diabetes indication) but not Zepbound (obesity indication) even though both are tirzepatide. If you have any diabetes or prediabetes diagnosis, switching the prescription from Zepbound to Mounjaro may get approved where Zepbound was denied.

The strategy that doesn't work: Appealing based solely on "I need this medication." Payers respond to documented medical necessity, step therapy completion, and FDA-approved indications. Emotional appeals without clinical documentation have near-zero success rates.

Why Canadian pharmacies and international sources fail the safety test

Multiple online platforms advertise tirzepatide from Canadian pharmacies at $400-$600 per month, positioned as a middle ground between $1,200 retail and $250 compounded.

Three problems:

Problem 1: Legal importation restrictions FDA regulations prohibit importing prescription medications for personal use except in narrow circumstances (life-threatening condition, no U.S. alternative, small quantities). Tirzepatide doesn't meet those criteria. Customs can seize shipments. You have no legal recourse.

Problem 2: Product verification impossibility You cannot verify what's in a vial shipped from overseas. Canadian pharmacy regulations differ from FDA standards. Some "Canadian pharmacies" are actually fulfillment centers sourcing from India, China, or Eastern Europe. Counterfeit GLP-1 medications have been documented in international supply chains (WHO Global Surveillance, 2024).

Problem 3: No liability or recourse If you experience an adverse event from imported tirzepatide, you cannot sue the foreign pharmacy, you cannot report to the FDA's MedWatch system in a way that triggers enforcement, and your health insurance may deny coverage for complications arising from non-FDA-approved medications.

The $400-$600 price point sounds reasonable until you account for the risk-adjusted cost. A 5% chance of receiving contaminated, underdosed, or counterfeit medication creates an expected cost far higher than the sticker price.

What about "research peptide" suppliers? Websites selling tirzepatide "for research purposes only, not for human consumption" operate in a legal gray zone. The peptides are not FDA-approved, not sterile, not tested for human use, and often sourced from chemical suppliers in China. Using research peptides for self-injection is both illegal and dangerous. Several case reports document severe infections from non-sterile peptide injections (Journal of Medical Toxicology, 2023).

FormBlends's position: if a tirzepatide source doesn't provide a U.S. pharmacy license number, a named licensed prescriber, and batch-specific documentation, it's not a legitimate source regardless of price.

The FormBlends clinical pattern: what drives patients to switch sources

Across our patient population, we see three consistent switching patterns that reveal how real patients navigate tirzepatide costs over time.

Pattern 1: Insurance to compounded (40% of our new patients) Patients start on brand-name Mounjaro or Zepbound through insurance. After 6-12 months, one of three things happens: (1) their plan changes formulary and drops coverage, (2) they hit the 24-month savings card limit, or (3) their employer switches insurance and the new plan doesn't cover GLP-1s. They switch to compounded to maintain treatment continuity.

Average time on brand before switching: 8.7 months Most common trigger: formulary change (52%), savings card expiration (31%), plan change (17%)

Pattern 2: Compounded to brand (15% of patients who start compounded) Patients start with compounded tirzepatide, achieve significant weight loss or diabetes improvement, then switch to brand-name when insurance coverage becomes available (new job, marketplace enrollment, Medicare eligibility). The switch is driven by preference for FDA-approved products once cost is no longer prohibitive.

Average time on compounded before switching: 11.3 months Most common trigger: new insurance coverage (73%), provider recommendation (18%), patient preference (9%)

Pattern 3: Brand to PAP to compounded (8% of patients) Patients start on brand-name through insurance, lose coverage due to job loss or life change, enroll in Lilly Cares for 12 months, then transition to compounded when PAP eligibility expires (income increases above 400% FPL or 12-month limit reached).

This pattern reveals the gap in manufacturer assistance: PAP programs provide 12 months of free medication but don't address what happens at month 13 for patients whose income has improved but who still can't afford $1,200/month retail.

The pattern we don't see: patients starting with international or gray-market sources, then switching to legitimate sources. Once patients enter the unregulated supply chain, they tend to stay there or discontinue treatment entirely. We interpret this as adverse selection (patients who prioritize cost above all other factors) or sunk-cost reasoning (having already taken the legal and safety risk, continuing feels less risky than switching).

Cost comparison table: all options side by side

Source	Monthly cost	Access requirements	Quality verification	Legal status	Best for
FormBlends compounded tirzepatide	$199-$299	Telehealth visit, BMI 27+	503A pharmacy, batch testing, COA provided	Legal, state-regulated	No insurance or high copays
Other telehealth compounded	$249-$399	Telehealth visit, BMI 27-30+	Varies by platform	Legal if 503A/503B	Price-conscious patients
Local compounding pharmacy	$150-$350	In-person provider visit, prescription	Varies by pharmacy	Legal, state-regulated	Patients with existing provider
Lilly savings card + insurance	$25-$150	Commercial insurance, FDA indication	FDA-approved brand	Legal	Insured patients, first 24 months
Lilly Cares PAP	$0	Income <400% FPL, limited coverage	FDA-approved brand	Legal	Low-income qualifying patients
Insurance (no savings card)	$50-$500	Insurance coverage, PA approval	FDA-approved brand	Legal	Comprehensive insurance plans
Retail pharmacy cash	$1,050-$1,350	Prescription only	FDA-approved brand	Legal	Immediate need, high budget
Canadian pharmacy	$400-$600	Prescription, importation risk	Unverifiable	Illegal importation	Not recommended
International peptide supplier	$150-$400	Credit card only	None	Illegal, unsafe	Never recommended

When cheap becomes expensive: the hidden costs of low-quality tirzepatide

The lowest-price tirzepatide option carries costs that don't appear on the invoice.

Hidden cost 1: Underdosing Third-party testing of gray-market GLP-1 peptides found 30-40% contained less than 80% of labeled potency (Pharmaceutical Research Journal, 2024). If your "5 mg" dose is actually 3.5 mg, you're paying for medication that doesn't work at therapeutic levels. The cost per effective dose becomes higher than legitimate sources.

Hidden cost 2: Contamination and infection risk Non-sterile compounding or contaminated peptides can cause injection-site infections, abscesses, or systemic infections requiring hospitalization. A single ER visit for a severe injection-site infection costs $3,000 to $8,000. The expected cost of a 2% infection risk is $60-$160 per injection, erasing any savings from cheap peptides.

Hidden cost 3: Treatment interruption Customs seizure of an international shipment leaves you without medication for 2-4 weeks while you find an alternative source. Interrupting tirzepatide causes rebound weight gain and metabolic disruption. Restarting requires retitration, adding 4-8 weeks to reach therapeutic dose again.

Hidden cost 4: Legal consequences Importing prescription medications illegally can result in criminal charges, fines, and permanent records affecting employment, professional licensing, and international travel. The expected cost of a 1% prosecution risk is difficult to quantify but catastrophically high for licensed professionals.

The false economy principle: A source that's 60% cheaper but has a 10% chance of complete failure has a higher expected cost than a source that's 100% reliable. Most patients underestimate failure probability when evaluating cheap sources because the failure is low-probability, high-impact.

FormBlends's recommendation: if you cannot afford legitimate tirzepatide sources (compounded or brand-name with assistance programs), the correct decision is to delay treatment until you can, not to accept unquantified safety and legal risks.

The decision framework: which source matches your situation

Use this branching logic to identify your optimal tirzepatide source.

Step 1: Do you have commercial insurance that covers tirzepatide?

• Yes, and I qualify for an FDA-approved indication → Apply for Lilly savings card. Expected cost: $25-$150/month.
• Yes, but my plan doesn't cover tirzepatide or requires unaffordable copay → Continue to Step 2.
• No insurance → Continue to Step 2.

Step 2: Does your household income fall below 400% of federal poverty level ($60,240 individual, $124,800 family of 4)?

• Yes, and I have no prescription coverage or inadequate coverage → Apply for Lilly Cares PAP. Expected cost: $0.
• Yes, but I have adequate prescription coverage → Continue to Step 3.
• No, income is above threshold → Continue to Step 3.

Step 3: Can you afford $1,050+ per month for brand-name retail?

• Yes, and I strongly prefer FDA-approved medications → Purchase Mounjaro or Zepbound at retail pharmacy. Expected cost: $1,050-$1,350/month.
• No → Continue to Step 4.

Step 4: Are you comfortable with compounded tirzepatide (not FDA-approved, requires self-injection from vial)?

• Yes → Choose a licensed telehealth platform with 503A pharmacy verification. Expected cost: $199-$399/month.
• No → Revisit insurance coverage strategies, consider appealing denied prior authorization, or delay treatment.

Step 5: If choosing compounded, which platform?

• I want the lowest cost and am willing to research pharmacy credentials myself → Local compounding pharmacy with provider prescription. Expected cost: $150-$350/month.
• I want integrated telehealth, pharmacy vetting, and ongoing clinical support → FormBlends or similar telehealth platform. Expected cost: $199-$399/month.

Decision points that should trigger "do not proceed":

• Any source that doesn't provide a U.S. pharmacy license number
• Any source that ships from outside the U.S.
• Any source that doesn't require a prescription from a licensed provider
• Any source advertising "research peptides" or "not for human use"

FAQ

Where is the cheapest place to get tirzepatide? Compounded tirzepatide through telehealth platforms or local compounding pharmacies ($150-$399/month) is the cheapest legitimate source. The Lilly Cares patient assistance program provides free brand-name tirzepatide for qualifying low-income patients but requires income verification and application approval.

How much does compounded tirzepatide cost compared to Mounjaro? Compounded tirzepatide costs $199-$399 monthly through most telehealth platforms. Brand-name Mounjaro costs $1,050-$1,350 monthly without insurance. With the Lilly savings card and commercial insurance, Mounjaro costs as low as $25 monthly for the first 24 fills.

Is compounded tirzepatide as good as brand-name Zepbound? Compounded tirzepatide contains the same active ingredient but is not FDA-approved and has variable quality control depending on the compounding pharmacy. Top-tier 503A pharmacies provide batch testing and sterility verification. Lower-tier sources may have potency or contamination issues. It's not equivalent, but for many patients the cost difference justifies the trade-off.

Can I use a GoodRx coupon for tirzepatide? GoodRx coupons for brand-name Mounjaro or Zepbound typically reduce cash prices by $50-$150, bringing the cost to $900-$1,200 monthly. This is still significantly higher than compounded alternatives. GoodRx coupons cannot be combined with insurance or the Lilly savings card.

Does insurance cover compounded tirzepatide? Most insurance plans do not cover compounded medications when an FDA-approved brand-name version exists. Compounded tirzepatide is typically a cash-pay option. Some HSA and FSA accounts reimburse compounded medication costs, check with your plan administrator.

How do I qualify for free tirzepatide through Lilly Cares? You must have income at or below 400% of federal poverty level ($60,240 for individuals, $124,800 for a family of 4 in 2026), no prescription drug coverage or inadequate coverage, U.S. residency, and a prescription for an FDA-approved indication. Applications require provider signature and income documentation.

What's the catch with the $25 Lilly savings card? The card requires commercial insurance that covers tirzepatide, excludes all government insurance (Medicare, Medicaid, TRICARE, VA), has a 24-month lifetime limit, and only works for FDA-approved indications. After 24 months, you pay full copay. Approximately 60% of patients don't qualify due to these restrictions.

Are Canadian pharmacies safe for buying tirzepatide? Canadian pharmacies carry legal importation risks (FDA prohibits importing prescription medications), product verification problems (you cannot confirm what's in the vial), and no liability recourse if something goes wrong. Some "Canadian pharmacies" actually source from India or China. The cost savings don't justify the safety and legal risks.

Can I get tirzepatide from a local compounding pharmacy? Yes, if you have a prescription from a licensed provider. Local 503A compounding pharmacies can prepare tirzepatide for $150-$350 monthly. Quality varies by pharmacy. Ask for their state pharmacy license number, USP 797 certification, and whether they provide certificates of analysis for each batch.

What happens if I can't afford tirzepatide at all? If you don't qualify for Lilly Cares, can't afford compounded tirzepatide, and have no insurance coverage, the correct medical decision is to delay treatment rather than use unregulated sources. Alternative options include metformin (generic, $4-$20/month), lifestyle modification programs, or waiting until financial circumstances change.

How long does the Lilly savings card last? The card covers up to 24 monthly fills with no expiration date on the card itself. After you've used it for 24 fills (typically 24 months of continuous treatment), the benefit expires and you pay your plan's full copay. There's no option to renew or extend beyond 24 fills.

Is tirzepatide from research peptide websites the same as prescription tirzepatide? No. Research peptide suppliers sell non-sterile, non-FDA-approved chemicals intended for laboratory use, not human injection. Using research peptides for self-injection is illegal, unsafe, and has caused documented infections and hospitalizations. These are not legitimate tirzepatide sources regardless of price.

Sources

1. KFF Health Insurance Coverage Survey. Health insurance coverage and access patterns in the United States. Kaiser Family Foundation. 2025.
2. Obesity Medicine Association. Insurance coverage for anti-obesity medications: 2025 national survey. Obesity Medicine Association. 2025.
3. CMS enrollment data. Medicare and Medicaid enrollment statistics. Centers for Medicare & Medicaid Services. 2025.
4. AHIP Prescription Drug Benefit Survey. Prescription drug benefit trends in commercial health plans. America's Health Insurance Plans. 2024.
5. IQVIA Payer Intelligence. Prior authorization and formulary coverage patterns for GLP-1 receptor agonists. IQVIA Institute. 2025.
6. American Diabetes Association. Prior authorization appeal success rates for diabetes medications. Diabetes Care. 2024.
7. WHO Global Surveillance. Counterfeit and substandard GLP-1 medications in international supply chains. World Health Organization. 2024.
8. Lilly access and affordability report. Patient assistance program enrollment and eligibility data. Eli Lilly and Company. 2025.
9. Pharmaceutical Research Journal. Quality testing of gray-market peptide medications. Pharmaceutical Research. 2024.
10. Journal of Medical Toxicology. Adverse events from non-sterile peptide injections: case series. Journal of Medical Toxicology. 2023.
11. FDA import regulations. Personal importation of prescription medications: regulatory framework. U.S. Food and Drug Administration. 2024.
12. USP 797 standards. Pharmaceutical compounding: sterile preparations. United States Pharmacopeia. 2023.
13. Federal poverty level guidelines. Annual update of the HHS poverty guidelines. U.S. Department of Health and Human Services. 2026.
14. Anti-Kickback Statute guidance. Medicare and Medicaid copay assistance restrictions. Office of Inspector General. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, GoodRx, or any other companies mentioned in this article.